16.08

4.62% 0.71

After Hours: 16.92 0.84 +5.22%

Evommune Inc (EVMN)

Overview News Price History Discussions Forecast

Evommune Inc stock is traded at $16.08, with a volume of 403.99K. It is up +4.62% in the last 24 hours and down -26.58% over the past month. Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Previous Close:

$15.37

Open:

$15.5

24h Volume:

403.99K

Relative Volume:

3.78

Market Cap:

$506.91M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-8.22%

1M Performance:

-26.58%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$15.30

$16.41

1-Week Range:

$14.77

$18.05

52-Week Range:

$13.88

$24.03

Evommune Inc Stock (EVMN) Company Profile

Name

Evommune Inc

Sector

Healthcare (1114)

Industry

Biotechnology (625)

Phone

(650) 223-7745

Address

1841 PAGE MILL RD, PALO ALTO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

EVMN's Discussions on Twitter

Compare EVMN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EVMN Evommune Inc	16.08	484.53M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Evommune Inc Stock (EVMN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-26	Initiated	H.C. Wainwright	Buy
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight
Dec-01-25	Initiated	Evercore ISI	Outperform
Dec-01-25	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight
Dec-01-25	Initiated	William Blair	Outperform

View All

Evommune Inc Stock (EVMN) Latest News

Jan 06, 2026

Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch - TipRanks

Jan 06, 2026

Evommune stock initiated with Buy rating at H.C. Wainwright on urticaria potential - Investing.com Nigeria

Jan 06, 2026

This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga

Jan 06, 2026

Evommune initiated with a Buy at H.C. Wainwright - TipRanks

Jan 06, 2026

Dec 31, 2025

The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stock - The Business Journals

Dec 31, 2025

Dec 26, 2025

Hopfner buys Evommune (EVMN) shares worth $17,350 By Investing.com - Investing.com Nigeria

Dec 22, 2025

Hopfner buys Evommune (EVMN) shares worth $17,350 - Investing.com India

Dec 22, 2025

Dec 21, 2025

Evommune, Inc.(NYSE: EVMN) added to S&P TMI Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

Aktis Oncology files for US IPO as biotech listings rebound - Reuters

Dec 19, 2025

Evommune (EVMN) awards 100,000 stock options to its Chief Medical Officer - Stock Titan

Dec 19, 2025

Evommune Prepares For Key Mid-2026 Trial Readouts, Advances Inflammation Pipeline - RTTNews

Dec 19, 2025

Dec 15, 2025

Silicon Valley biotech firm expands to 43,000 square feet after going public - The Business Journals

Dec 15, 2025

Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential - TipRanks

Dec 15, 2025

Dec 13, 2025

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail

Dec 13, 2025

Dec 12, 2025

These Bay Area companies are IPO contenders in 2026 - The Business Journals

Dec 12, 2025

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace

Dec 12, 2025

Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks

Dec 12, 2025

Dec 11, 2025

CEO Pena Surrenders 28,138 Of Evommune Inc [EVMN] - TradingView — Track All Markets

Dec 11, 2025

Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets

Dec 11, 2025

EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets

Dec 11, 2025

Evommune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com

Dec 11, 2025

EVMN: IPO proceeds and licensing revenue strengthen position ahead of key 2026 clinical readouts - TradingView — Track All Markets

Dec 11, 2025

Dec 09, 2025

Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times

Dec 09, 2025

Dec 06, 2025

Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat

Dec 06, 2025

Dec 05, 2025

Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech

Dec 05, 2025